MarketPulse

Anktiva drug

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

ImmunityBio Securities Fraud Lawsuit: Investors Sought for Class Action Over Anktiva Claims

Schall Law Firm recruits ImmunityBio investors for securities fraud class action over alleged false Anktiva drug statements between January-March 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

ImmunityBio Faces Securities Fraud Lawsuit Over Misleading Anktiva Claims

ImmunityBio faces class action securities fraud lawsuit over allegedly false Anktiva drug claims. Schall Law Firm recruiting investors who purchased stock January-March 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

ImmunityBio Hit With Securities Fraud Suit Over Cancer Cure Claims

ImmunityBio faces class action lawsuit after FDA warning letter over false cancer claims by Executive Chairman Patrick Soon-Shiong. Stock plunged 21%.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

ImmunityBio Securities Fraud Class Action Seeks Investors Amid Anktiva Claims

Schall Law Firm launches class action lawsuit against ImmunityBio for alleged securities fraud over false Anktiva drug statements between January-March 2026.
IBRXsecurities fraudclass action lawsuit